Related Experiment Videos
[Glucocorticoids and multiple myeloma. Mechanism of action, resistance and clinical use]
Abstract:
The fundamental and clinical backgrounds for the use of glucocorticoids in multiple myeloma are reviewed. Glucocorticoids induce apoptosis and alter the cellular cycle of malignant cells, interacting with the effects of IL-6. The number of normal or variant glucocorticoid receptors expressed by the tumoral cells and the corticoresistant secretion by stromal cells of IL-6 and its soluble receptor are implicated in resistance to glucocorticoids. Given alone or in association with vincristin and adriamycin, glucocorticoids induce major cytoreduction in tumors and is best used in refractory and relapsing diseases.
Insights
Glucocorticoids are effective in treating multiple myeloma by inducing cancer cell death and cell cycle changes. They are particularly useful for relapsed or refractory cases, alone or with other therapies.
Area of Science:
- Oncology
- Pharmacology
Context:
- Multiple myeloma is a hematologic malignancy.
- Glucocorticoids are established therapeutic agents.
Purpose:
- To review the role of glucocorticoids in multiple myeloma treatment.
- To explore mechanisms of glucocorticoid action and resistance.
Summary:
- Glucocorticoids induce apoptosis and alter the cell cycle of multiple myeloma cells, counteracting IL-6 effects.
- Resistance mechanisms involve glucocorticoid receptor expression and stromal cell IL-6 secretion.
- Glucocorticoids, alone or with vincristine and adriamycin, achieve significant tumor reduction, especially in refractory/relapsing disease.
Impact:
- Highlights glucocorticoid efficacy in multiple myeloma, particularly in resistant cases.
- Identifies key factors influencing glucocorticoid response and resistance.
- Provides rationale for combination therapy strategies.